Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Kenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

"Tirzepatide is currently FDA-approved for treating Type 2 diabetes, but it is being fast-tracked through the FDA to receive an indication for the treatment of obesity," Dr. Fatima Stanford of ...

The new tirzepatide trial, called SURMOUNT-1, included more than 2,500 volunteers who either met the medical definition of obesity, having a body mass index of 30 or above, or had a slightly lower ...